Chromocell Therapeutics Corporation reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 2.46 million compared to USD 0.595387 million a year ago. Basic loss per share from continuing operations was USD 5.67.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.19 USD | +1.71% | +7.69% | 0.00% |
Jun. 24 | Chromocell Therapeutics Corporation(NYSEAM:CHRO) added to S&P TMI Index | CI |
May. 15 | Chromocell Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 6.88M | |
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |
- Stock Market
- Equities
- CHRO Stock
- News Chromocell Therapeutics Corporation
- Chromocell Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022